Bone as a source of organism vitality and regeneration

Folia Histochemica et Cytobiologica

Volumn 49, Issue 4, 2011, Pages 558-569

  Mackiewicz, Zygmunt ^a,b   Niklińska, Wiesława Ewa ^b   Kowalewska, Jolanta ^b   Chyczewski, Lech ^b  

^a State Research Institute Centre for Innovative Medicine   (Lithuania)

^b MEDICAL UNIVERSITY OF BIALYSTOK   (Poland)

Author keywords

Bone; Bone derived adult stem cells; Osteoblasts; Osteoclasts; Osteocytes; Osteoporosis

Indexed keywords

CALCIUM; GLUCOCORTICOID; OSTEOCLAST DIFFERENTIATION FACTOR; RECEPTOR ACTIVATOR OF NUCLEAR FACTOR KAPPA B; WNT PROTEIN;

ADULT STEM CELL; BONE DEVELOPMENT; BONE MATRIX; BONE REGENERATION; BONE REMODELING; BONE STRUCTURE; CELL ACTIVATION; CELL ACTIVITY; CELL DIFFERENTIATION; CELL THERAPY; ENZYME REGULATION; HUMAN; INFLAMMATORY DISEASE; INTERVERTEBRAL DISK DISEASE; JOINT PROSTHESIS; KNOWLEDGE; MESENCHYMAL STROMA CELL; MOLECULAR DYNAMICS; NONHUMAN; OBESITY; OSSIFICATION; OSTEOBLAST; OSTEOCYTE; OSTEOLYSIS; OSTEOPOROSIS; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN PROTEIN INTERACTION; REVIEW; SIDE EFFECT;

EID: 84856773209     PISSN: 02398508     EISSN: 18975631     Source Type: Journal    
DOI: 10.5603/FHC.2011.0079     Document Type: Review

References (114)

1. Weinstein SL. 2000-2010: The bone and joint decade. J Bone Joint Surg Am. 2000;82:1-3.
2. th Ed., edited by Standring S, New York, Elsevier. 2004;83-135.
3. Clarke B. Normal bone anatomy and physiology. Clin J Am Soc Nephrol. 2008;3:S131-S139.
4. Taichman RS. Blood and bone: Two tissues whose fates are intertwined to create the hematopoietic stem cell niche. Blood. 2005;105:2631-2639.
5. Katagiri T, Takahashi N. Regulatory mechanisms of osteoblast and osteoclast differentiation. Oral Dis. 2002;8:147-159.
6. Neumann E, Schett G. Bone metabolism: molecular mechanisms. Z Rheumatol. 2007;66:286-289.
7. Jorgensen NR, Teilmann SC, Henriksen Z, Civitelli R, Sorensen OH, Steinberg TH. Activation of L-type calcium channels is required for gap junction-mediated intercellular calcium signaling in osteoblastic cells. J Biol Chem. 2003;278:4082-4086.
8. Frost HM. Wolf's Law and bone's structural adaptation to mechanical usage: an overview for clinicians. Angle Orthod. 1994;64:175-188.
9. Bonewald LF, Johnson ML. Osteocytes, mechanosensing and Wnt signaling. Bone. 2008;42:606-615.
10. Xing L, Boyce BF. Regulation of apoptosis in osteoclasts and osteoblastic cells. Biochem Biophys Res Commun. 2005; 328:709-720.
11. Plotkin LI, Aguirre JI, Kousteni S, Manolagas SC, Bellido T. Bisphosphonates and estrogens inhibit osteocyte apoptosis via distinct molecular mechanisms downstream of extracellular signal-regulated kinase activation. J Biol Chem. 2005;280:7317-7325.
12. Manolagas SC, Jilka RL. Bone marrow, cytokines, and bone remodeling. Emerging insights into the pathophysiology of osteoporosis. N England J Med. 1995;332:305-311.
13. Harel Z. Bone metabolism during adolescence: the known, the unknown, and the controversial. Adolesc Med State Art Rev. 2008;19:573-591.
14. Karsenty G, Wagner EF. Reaching a genetic and molecular understanding of skeletal development. Dev Cell. 2002;2:389-406.
15. Del Fattore A, Cappariello A, Teti A. Genetics, pathogenesis and complications of osteopetrosis. Bone. 2008;42:19-29.
16. Lian JB, Stein GS. Runx2/Cbfa1: a multifunctional regulator of bone formation. Curr Pharm Des. 2003;9:2677-2685.
17. Blair HC, Athanasou NA. Recent advances in osteoclast biology and pathological bone resorption. Histol Histopathol. 2004;19:189-199.
18. Reddy SV. Regulatory mechanisms operative in osteoclasts. Crit Rev Eukaryot Gene Exp. 2004;14:255-270.
19. Deal C. Future therapeutic targets in osteoporosis. Curr Opin Rheumatol. 2009;21:380-385.
20. Anderson DM, Maraskovsky E, Billingsley WL et al. A homologue of the TNF receptor and its ligand enhance T-cell growth and dendritic-cell function. Nature. 1997;390: 175-179.
21. Wada T, Nakashima T, Hiroshi N, Penninger JM. RANKL- -RANK signaling in osteoclastogenesis and bone disease. Trends Mol Med. 2006;12:17-25.
22. Proff P, Römer P. The molecular mechanism behind bone remodelling: a review. Clin Oral Investig. 2009;13:355-362.
23. Gallagher JC. Advances in bone biology and new treatments for bone loss. Maturitas. 2008;60:65-69.
24. Datta HK, Ng WF, Walker JA, Tuck SP, Varanasi SS. The cell biology of bone metabolism. J Clin Pathol. 2008;61:577-587.
25. Mackiewicz Z, Salo J, Konttinen YT et al. Receptor activator of nuclear factor kappa B ligand in an experimental intervertebral disc degeneration. Clin Exp Rheumatol. 2009;27:299-306.
26. Salo J, Mackiewicz Z, Indahl A et al. Plasmin-matrix metalloproteinase cascades in spinal response to an experimental disc lesion in pig. Spine. 2008;33:839-844.
27. Holm S, Mackiewicz Z, Holm AK et al. Pro-inflammatory, pleiotropic and anti-inflammatory TNF-a, IL-6 and IL-10 in experimental porcine intervertebral disc degeneration. Vet Pathol. 2009;46:1292-1230.
28. Boyce BF, Xing L. Functions of the RANK/RANKL/OPG in bone modelling and remodelling. Arch Biochem Biophys. 2008;473:139-146.
29. Kong YY, Boyle WJ, Penninger JM. Osteoprotegerin ligand: a regulator of immune responses and bone physiology. Immunol Today. 2000;21:495-502.
30. Del Fattore A, Peruzzi B, Rucci N et al. Clinical, genetic, and cellular analysis of 49 osteopetrotic patients: implications for diagnosis and treatment. J Med Genet. 2006;43:315-325.
31. Kearns AE, Khosla S, Kostenuik P. RANKL and OPG regulation of bone remodeling in health and disease. Endocr Rev. 2008,29:155-192.
32. Hofbauer LC, Khosla S, Dunstan CR, Lacey DL, Boyle WJ, Riggs BL. The roles of osteoprotegerin and osteoprotegerin ligand in the paracrine regulation of bone resorption. J Bone Mineral Res. 2000;15:2-12.
33. Hofbauer LC, Schoppet M. Clinical implications of the osteoprotegerin/ RANKL/RANK system for bone and vascular diseases. JAMA. 2004;292:490-495.
34. Smit TH, Burger EH, Huyghe JM. A case for strain-induced fluid flow as a regulator of BMU-coupling and osteonal alignment. J Bone Miner Res. 2002;17:2021-2029.
35. Hauge EM, Qvesel D, Eriksen EF, Mosekilde L, Melsen F. Cancellous bone remodeling occurs in specialized compartments lined by cells expressing osteoblastic markers. J Bone Miner Res. 2001;16:1575-1582.
36. 3 and macrophage colony-stimulating factor: Partners in osteoclast biology. Immunol Rev. 2005;208:88-105.
37. Teitelbaum SL, Ross FP. Genetic regulation of osteoclast development and function. Nat Revs Genet. 2003;4:638-649.
38. Boyce BF, Xing L, Shakespeare W et al. Regulation of bone remodeling and emerging breakthrough drugs for osteoporosis and osteolytic bone metastases. Kidney Int Suppl. 2003:2-5.
39. Kollet O, Dar A, Shivtiel S et al. Osteoclasts degrade endosteal components and promote mobilization of hematopoietic progenitor cells. Nat Med. 2006;12:657-664.
40. Xing L, Schwarz EM, Boyce BF. Osteoclast precursors, RANKL/RANK, and immunology. Immunol Rev. 2005;208: 19-29.
41. Feng JQ, Ye L, Schiavi S. Do osteocytes contribute to phosphate homeostasis? Curr Opin Nephrol Hypertens. 2009;18: 285-291.
42. + wasting, hyperabsorption, and reduced bone thickness in mice lacking TRPV5. J Clin Invest. 2003;112:1906-1914.
43. Taylor JG, Bushinsky DA. Calcium and phosphorus homeostasis. Blood Purif. 2009;27:387-394.
44. Hurwitz S. Homeostatic control of plasma calcium concentration. Crit Rev Biochem Mol Biol. 1996;31:41-100.
45. + channels in small intestine as studied by quantitative mRNA detection. Am J Physiol Gastrointest Liver Physiol. 2003;285: G78-G85.
46. Lee M, Partridge NC. Parathyroid hormone signaling in bone and kidney. Curr Opin Nephrol Hypertens. 2009;18:298-302.
47. Brown EM. The calcium-sensing receptor: physiology, pathophysiology and CaR-based therapeutics. Subcell Biochem. 2007;45:139-167.
48. Teti A, Zallone A. Do osteocytes contribute to bone mineral homeostasis? Osteocytic osteolysis revisited. Bone. 2009;44:11-16.
49. Boneweald LF. The amazing osteocyte. J Bone Miner Res. 2011;26:229-238.
50. Nakahama K. Cellular communications in bone homeostasis and repair. Cell Mol Life Sci. 2010;67:4001-4009.
51. Eriksen EF. Cellular mechanisms of bone remodelling. Rev Endocr Metab Disor. 2010;11:219-227.
52. Logan CY, Nusse R. The Wnt signaling pathway in development and disease. Annu Rev Cell Dev Biol. 2004;20:781-810
53. Omelon S, Georgiou J, Henneman ZJ et al. Control of vertebrate skeletal mineralization by polyphosphates. PLoS ONE. 2009;4:e5634.
54. Smith AG. Embryo-derived stem cells: of mice and men. Annu Rev Cell Dev Biol. 2001;17:435-462.
55. Filip S, English D, Mokry J. Issues in stem cell plasticity. J Cell Mol Med. 2004;8:572-577.
56. Kindler V. Postnatal stem cell survival: does the niche, a rare harbor where to resist the ebb tide of differentiation, also provide lineage-specific instructions? J Leukoc Biol. 2005; 78:836-844.
57. Group SCTC. Allogeneic peripheral blood stem-cell compared with bone marrow transplantation in the management of hematologic malignancies: an individual patient data meta-analysis of nine randomized trials. J Clin Oncol. 2005;23:5074-5087.
58. Rashedi I, Panigrahi S, Ezzati P, Ghavami S, Los M. Autoimmunity and apoptosis - therapeutic implications. Curr Med Chem. 2007;14:3139-3159.
59. Bryder D, Rossi DJ, Weissman IL. Hematopoietic stem cells: the paradigmatic tissue-specific stem cell. Am J Pathol. 2006;169:338-346.
60. +Linsubpopulation from mobilized peripheral blood. Blood. 1995;85:368-378.
61. +/CD38 low/- precursors. Br J Haematol. 2000;108:610-620.
62. Ferrari G, Cusella-De Angelis G, Coletta M et al. Muscle regeneration by bone marrow-derived myogenic progenitors. Science. 1998;279:1528-1530.
63. Petersen BE, Bowen WC, Patrene KD et al. Bone marrow as a potential source of hepatic oval cells. Science. 1999; 284:1168-1170.
64. Orlic D, Kajstura J, Chimenti S et al. Bone marrow cells regenerate infarcted myocardium. Nature. 2001;410:701-705.
65. Liao R, Pfister O, Jain M, Mouquet F. The bone marrowcardiac axis of myocardial regeneration. Prog Cardiovasc Dis. 2007;50:18-30.
66. Li H, Malhotra D, Yeh CC et al. Myocardial survival signaling in response to stem cell transplantation. J Am Coll Surg. 2009;208:607-613.
67. Brazelton TR, Rossi FM, Keshet GI, Blau HM. From marrow to brain: expression of neuronal phenotypes in adult mice. Science. 2000;290:1775-1779.
68. Walsh S, Midha R. Practical considerations concerning the use of stem cells for peripheral nerve repair. Neurosurg Focus. 2009;26:E2.
69. Jackson KA, Majka SM, Wang H et al. Regeneration of ischemic cardiac muscle and vascular endothelium by adult stem cells. J Clin Invest. 2001;107:1395-1402.
70. Lagasse E, Connors H, Al-Dhalimy M et al. Purified hematopoietic stem cells can differentiate into hepatocytes in vivo. Nat Med. 2000;6:1229-1234.
71. Krause DS, Theise ND, Collector MI et al. Multi-organ, multilineage engraftment by a single bone marrow-derived stem cell. Cell. 2001;105:369-377.
72. Kopen GC, Prockop DJ, Phinney DG. Marrow stromal cells migrate throughout forebrain and cerebellum, and they differentiate into astrocytes after injection into neonatal mouse brains. Proc Natl Acad Sci USA. 1999;96: 10711-10716.
73. Ott HC, Bonaros N, Marksteiner R et al. Combined transplantation of skeletal myoblasts and bone marrow stem cells for myocardial repair in rats. Eur J Cardiothorac Surg. 2004;25:627-634.
74. Alexander HK, Booy EP, Xiao W, Ezzati P, Baust H, Los M. Selected technologies to control genes and their products for experimental and clinical purposes. Arch Immunol Ther Exp. 2007;55:139-149.
75. Odelberg SJ, Kollhoff A, Keating MT. Dedifferentiation of mammalian myotubes induced by msx1. Cell. 2000;103:1099-1109.
76. Tsai RY, Kittappa R, McKay RD. Plasticity, niches, and the use of stem cells. Dev Cell. 2002;2:707-712.
77. Chen S, Zhang Q, Wu X, Schultz PG, Ding S. Dedifferentiation of lineage-committed cells by a small molecule. J Am Chem Soc. 2004;126:410-411.
78. Chen CJ, Ou YC, Liao SL et al. Transplantation of bone marrow stromal cells for peripheral nerve repair. Exp Neurol. 2007;204:443-453.
79. Shimizu S, Kitada M, Ishikawa H et al. Peripheral nerve regeneration by the in vitro differentiated-human bone marrow stromal cells with Schwann cell property. Biochem Biophys Res Commun. 2007;359:915-920.
80. Tohill M, Mantovani C, Wiberg M et al. Rat bone marrow mesenchymal stem cells express glial markers and stimulate nerve regeneration. Neurosci Lett. 2004;362:200-203.
81. Wang D, Liu XL, Zhu JK et al. Bridging small-gap peripheral nerve defects using acellular nerve allograft implanted with autologous bone marrow stromal cells in primates. Brain Res. 2008;1188:44-53.
82. Zhang P, He X, Liu K et al. Bone marrow stromal cells differentiated into functional Schwann cells in injured rat sciatic nerve. Artif Cells Blood Substit Immobil Biotechnol. 2004;32:509-518.
83. E. Horwitz, M. Andreef, F. Frassoni. Mesenchymal stromal cells. Biol Blood Marrow Transplant. 2007;13:53-57.
84. Le Blanc K, Rasmusson I., Sundberg B et al. Treatment of severe acute graft-versus-host disease with third party haploidentical mesenchymal stem cells. Lancet. 2004;363:1439-1441.
85. Brooke G, Cook M, Blair C et al. Therapeutic applications of mesenchymal stromal cells. Semin Cell Dev Biol. 2007;18:846-858.
86. Caplan AI. Adult mesenchymal stem cells for tissue engineering versus regenerative medicine. J Cell Physiol. 2007;213:341-347.
87. Horwitz EM, Gordon PL, Koo WK et al. Isolated allogeneic bone marrow-derived mesenchymal cells engraft and stimulate growth in children with osteogenesis imperfecta: implications for cell therapy of bone. Proc Natl Acad Sci USA. 2002;99:8932-8937.
88. Kon E, Muraglia A, Corsi A et al. Autologous bone marrow stromal cells loaded onto porous hydroxyapatite ceramic accelerated bone repair in critical-size defects of sheep long bones. J Biomed Mater Res. 2000;49:328-337.
89. Solchaga LA, Temenoff JS, Gao J, Mikos AG, Caplan AI, Goldberg VM. Repair of osteochondral defects with hyaluronan- and polyester-based scaffolds. Osteoarthritis Cartilage. 2005;13:297-309.
90. Ohgushi H, Kotobuki N, Funaoka H et al. Tissue engineered ceramic artificial joint-ex vivo osteogenic differentiation of patient mesenchymal cells on total ankle joints for treatment of osteoarthritis. Biomaterials. 2005;26:4654-4661.
91. Park H, Temenoff JS, Tabata Y, Caplan AI, Mikos AM. Injectable biodegradable hydrogel composites for rabbit marrow mesenchymal stem cell and growth factor delivery for cartilage tissue engineering. Biomaterials. 2007;28:3217-3227.
92. Maloney WJ, Sychterz C, Bragdon C, McGovern T, Jasty M, Engh CA. Skeletal response to well fixed femoral components inserted with and without cement. Clin Orthop. 1996;333:15-26.
93. Brisby H, Tao H, Ma DD, Diwan AD. Cell therapy for disc degeneration: potentials and pitfalls. Orthop Clin North Am. 2004; 35:85-93.
94. Hardy R, Cooper MS. Bone loss in inflammatory disorders. J Endocrinol. 2009;201:309-320.
95. Vico L, Collet P, Guignandon A et al. Effects of long-term microgravity exposure on cancellous and cortical weight-bearing bones of cosmonauts. Lancet. 2000;355:1607-1611.
96. LeBlanc AD, Spector ER, Evans HJ, Sibonga JD. Skeletal responses to space flight and the bed rest analog: a review. J Musculoskelet Neuronal Interact. 2007;7:33-47.
97. Lang T, LeBlanc A, Evans H, Lu Y, Genant H, Yu A. Cortical and trabecular bone mineral loss from the spine and hip in long-duration spaceflight. J Bone Miner Res. 2004;19:1006-1012.
98. LeBlanc AD, Schneider VS, Evans HJ, Engelbretson DA, Krebs JM. Bone mineral loss and recovery after 17 weeks of bed rest. J Bone Miner Res. 1990;5:843-850.
99. Hargens AR. Recent bed rest results and countermeasure development at NASA. Acta Physiol Scand. Suppl. 1994; 616:103-114.
100. LeBlanc AD, Driscol TB, Shackelford LC et al. Alendronate as an effective countermeasure to disuse induced bone loss. J Musculo Neuron Interact. 2002;2:235-243.
101. Rubin C, Gross T, Qin YX, Fritton S, Guilak F, McLeod K. Differentiation of the bone-tissue remodeling response to axial and torsional loading in the turkey ulna. J Bone Joint Surg Am. 1996;78:1523-1533.
102. Judex S, Gupta S, Rubin C. Regulation of mechanical signals in bone. Orthop Craniofac Res. 2009;12:94-104.
103. Guadalupe-Grau A, Fuentes T, Guerra B, Calbet JA. Exercise and bone mass in adults. Sports Med. 2009;39:439-468.
104. Rosen CJ, Klibanski A. Bone, fat, and body composition: evolving concepts in the pathogenesis of osteoporosis. Am J Med. 2009,122:409-414.
105. Dennison E, Mohamed MA, Cooper C. Epidemiology of osteoporosis. Rheum Dis Clin North Am. 2006;32:617-629.
106. Sipos W, Pietschmann P, Rauner M, Kerschan-Schindl K, Patsch J. Pathophysiology of osteoporosis. Wien Med Wochenschr. 2009;159:230-234.
107. Huang H, He X. Wnt/beta-catenin signaling: new (and old) players and new insights. Curr Opin Cell Biol. 2008;20:119-125.
108. Noble BS. The osteocyte lineage. Arch Biochem Biophys. 2008;473:106-111.
109. Glass DA 2nd, Karsenty G. In vivo analysis of Wnt signaling in bone. Endocrinology. 2007;148:2630-2634.
110. Hoeppner LH, Secreto FJ, Westendorf JJ. Wnt signaling as a therapeutic target for bone diseases. Expert Opin Ther Targets. 2009;13:485-496.
111. Gallagher JC, Sai AJ. Molecular biology of bone remodeling: implications for new therapeutic targets for osteoporosis. Maturitas. 2010;65:301-307.
112. Zaidi M. Skeletal remodeling in health and disease. Nat Med. 2007;13:791-801.
113. Vanderschueren D, Vandenput L, Boonen S, Lindberg MK, Bouillon R, Ohlsson C. Androgens and bone. Endocr Rev. 2004;25:389-425.
114. Emmelot-Vonk MH, Verhaar HJ, Nakhai Pour HR et al. Effect of testosterone supplementation on functional mobility, cognition, and other parameters in older men: a randomized controlled trial. JAMA. 2008;299:39-52.